Early- and Late-Stage Clinical Trials for the Spectrum of Alzheimer's Disease/Alzheimer's Disease-Related Dementias and Age-Related Cognitive Decline
Contract Overview
Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.
AI Contract Overview
The National Institute on Aging (NIA) plans to issue a Notice of Funding Opportunity (NOFO) aimed at supporting the development and implementation of clinical trials that target both early- and late-stage interventions for Alzheimer's disease (AD), Alzheimer's disease-related dementias (ADRD), and age-related cognitive decline. These interventions include both pharmacological and non-pharmacological approaches intended to prevent or treat cognitive, behavioral, and neuropsychiatric symptoms associated with these conditions. In addition to clinical trials, the funding opportunity will also encourage research designed to improve clinical trial design and methodologies within this field. While applications are not currently being accepted, the announcement serves to alert researchers with relevant expertise to start forming collaborations and preparing responsive projects. The NOFO will utilize the R01 mechanism, which supports investigator-initiated research. Researchers interested in aging-related cognitive health and dementia are encouraged to monitor the forthcoming solicitation and begin planning submissions. The point of contact for inquiries is Dr. Laurie Ryan at the National Institute on Aging.
General Info
Agency
NAICS
Place of Performance
Not specifiedSet-Aside
Documents
(0)AI Contract Breakdown
Uniform Contract FormatNo contract breakdown available.
Cannot generate Contract Breakdown because no documents were found from this contract's source.
Timeline
Organization & Contact Information
Full Description
The National Institute on Aging (NIA) intends to publish a Notice of Funding Opportunity (NOFO) to 1) invite applications that propose to develop and implement early- to late-stage clinical trials of promising pharmacological and non-pharmacological interventions to prevent and/or treat the cognitive, behavioral, and neuropsychiatric changes associated with age-related cognitive decline and Alzheimer's disease (AD) and Alzheimer's disease-related dementias (ADRD), and 2) stimulate studies to enhance trial design and methods. Applications are not being solicited at this time. Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. This NOFO intends to utilize the R01 activity code. Investigators with expertise and insights into this area of aging research are encouraged to begin to consider applying for this new NOFO.
